COSCIENS Biopharma Inc.

CSCI

Explore Our Financial Data > Companies > COSCIENS Biopharma Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	CSCI
CIK	0001113423
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	C/O NORTON ROSE FULBRIGHT CANADA LLP, 222 BAY STREET, SUITE 3000, PO BOX 53, TORONTO, A6, M5K 1E7
Website	www.cosciensbio.com
Phone	843-900-3201
CEO	Klaus W. Paulini
Employees	20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$9.68 million
Pre-Tax Income	$-15.22 million
Net Income	$-15.31 million
Net Income to Common	$-15.31 million
EPS	$-5.93

View All

Balance Sheet

Cash	$16.39 million
Assets	$35.07 million
Liabilities	$21.91 million
Common Equity	$8.89 million
Liabilities & Equity	$35.07 million

View All

Cash Flow Statement

Net Income	$-15.31 million
Cash From Operating Activities	$-14.48 million
Cash From Investing Activities	$0.00
Cash From Financing Activities	$0.00
Change in Cash	$-14.48 million

View All

Calculations

NOPAT	$-12.80 million
EBITDA	$-14.88 million
Price to Earnings	N/A
Price to Book	$1.36
ROE	-89.54%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the “AGSM”) held today. Results of the AGSM The results of the vote in res

Article Link

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement (the “Resolution Agreement”) with Goodwood Inc., Goodwood Fund and Puccetti Funds Management Inc. (collectively, “Goodwood”) to resolve matters relating to the upcoming annual and special meeting of COSCIENS’ shareholders that had been scheduled to be held on June 26, 2025 (the “2025 Annual Meeting”)

Article Link

Cosciens Biopharma announces receipt of Goodwood intended director nominations

Cosciens Biopharma (CSCI) confirmed that its board of directors has received a letter from Goodwood Fund and Puccetti Funds Management regarding six director nominations for the company’s upcoming annual and special meeting of shareholders. “We respectfully acknowledge receipt of the statement regarding the intentions from Goodwood and are carefully reviewing its contents,” said Ronnie Miller, Chair of the Board of Cosciens Biopharma. “With this in hand, the Board will evaluate and determine its

Article Link

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today confirmed that its Board of Directors has received a letter from Goodwood Fund and Puccetti Funds Management Inc.(“Goodwood”) regarding six (6) director nominations for the Company’s upcoming Annual and Special Meeting of

Article Link

Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.

Goodwood Fund and Puccetti Funds Management Inc. (collectively, "Goodwood") announced today that Goodwood has notified COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) that Goodwood intends to nominate six new highly qualified and experienced directors (the "Shareholder Nominees") for election at the upcoming annual and special meeting of COSCIENS' shareholders (the "Meeting") scheduled to be held on June 26, 2025.

Article Link